Bariatric venous thromboembolism prophylaxis: an update on the literature

dc.contributor.authorHamadi, Rachelle
dc.contributor.authorMarlow, Christina F.
dc.contributor.authorNassereddine, Samah
dc.contributor.authorTaher, Ali T.
dc.contributor.authorFinianos, Antoine
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:54:59Z
dc.date.available2025-01-24T11:54:59Z
dc.date.issued2019
dc.description.abstractIntroduction: Rates of obesity have been increasing worldwide and with the current situation obesity now represents an epidemic. Bariatric surgery is one the most effective ways to help reduce weight and sustain weight loss. Venous thromboembolism is a major cause of morbidity and mortality among bariatric surgery patients with no clearly established guidelines on prophylaxis. Areas covered: In this review the authors summarize clinical studies evaluating unfractionated heparin (UFH) and low molecular weight heparins (LMWH) in bariatric surgery patients. The authors present studies that assessed venous thromboembolic (VTE)-related risk stratification but also various dosing regimens of heparin products in this population of patients. Moreover, the authors will also present the feasibility of using direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention along with providing a summary of few current guidelines for VTE prevention in bariatric surgery patients. Expert opinion: Based on the data presented in this review, the authors conclude that LMWHs may be better options than UFH for VTE prophylaxis in bariatric surgery patients. We also conclude that risk stratifying bariatric patients may be a better approach when deciding on the best thromboprophylaxis modality, dose and duration. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.doihttps://doi.org/10.1080/17474086.2019.1634542
dc.identifier.eid2-s2.0-85070506806
dc.identifier.pmid31219356
dc.identifier.urihttp://hdl.handle.net/10938/31183
dc.language.isoen
dc.publisherTaylor and Francis Ltd
dc.relation.ispartofExpert Review of Hematology
dc.sourceScopus
dc.subjectAnti-xa
dc.subjectBariatric surgery
dc.subjectDirect oral anticoagulants
dc.subjectLow molecular weight heparin
dc.subjectProphylaxis. venous thromboembolism
dc.subjectAnticoagulants
dc.subjectBariatrics
dc.subjectFactor xa inhibitors
dc.subjectHeparin
dc.subjectHeparin, low-molecular-weight
dc.subjectHumans
dc.subjectVenous thromboembolism
dc.subjectBlood clotting factor 10a
dc.subjectAnticoagulant agent
dc.subjectBlood clotting factor 10a inhibitor
dc.subjectAnticoagulant therapy
dc.subjectAnticoagulation
dc.subjectEmbolism prevention
dc.subjectFeasibility study
dc.subjectHuman
dc.subjectPractice guideline
dc.subjectPriority journal
dc.subjectReview
dc.subjectSurgical patient
dc.subjectThrombosis prevention
dc.subjectAdverse event
dc.titleBariatric venous thromboembolism prophylaxis: an update on the literature
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019-7387.pdf
Size:
1000.2 KB
Format:
Adobe Portable Document Format